Application of tumor marker in liver cancer prognosis, severity evaluation and liver cancer treatment

By using THY1 as a marker of liver cancer, detection reagents for liver cancer severity assessment and prognosis assessment were developed, and by inhibiting THY1 gene expression, the complexity and cost of liver cancer prognosis assessment in the prior art were solved, and the problem of high cost of liver cancer in the prior art was achieved. Rapid and accurate evaluation and treatment effects of liver cancer.

CN119061144APending Publication Date: 2024-12-03SICHUAN ACADEMY OF MEDICAL SCI SICHUAN PROVINCIAL PEOPLES HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411313387.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-20
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The lack of reliable single markers in the prognosis of liver cancer in the prior art has led to high detection costs, complexity and inaccurate detection, making it difficult to effectively evaluate the severity and prognosis of liver cancer.

Method used

THY1 is used as a marker for liver cancer, and its gene expression inhibitor is developed for liver cancer prevention and treatment, and detection reagents are developed using the specific expression level of THY1 to achieve rapid and accurate assessment of liver cancer severity and prognosis.

Benefits of technology

By inhibiting THY1 gene expression, slowing the growth and metastasis of liver cancer and prolonging survival, it provides a low-cost, high-specific evaluation method for liver cancer severity, which can accurately predict the prognosis of patients with liver cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119061144A_ABST
    Figure CN119061144A_ABST
Patent Text Reader

Abstract

The invention discloses application of a tumor marker in liver cancer prognosis, severity evaluation and liver cancer treatment, and relates to the technical field of tumor prediction and evaluation. The THY1 is used as the liver cancer tumor marker, a corresponding reagent for detecting the level of the tumor marker can be developed, and the THY1 is further used for preparing liver cancer severity evaluation products or prognosis products. According to the tumor marker provided by the invention, evaluation of the severity and prognosis of the liver cancer can be quickly and accurately realized only by detecting one marker, and the application has the characteristics of low detection cost, simple result interpretation, accurate evaluation result, high specificity and the like. In addition, the growth speed, migration and invasion of the liver cancer can be slowed down by inhibiting the expression of the THY1 gene, and the THY1 gene can be used for preventing and treating the liver cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of tumor prediction and evaluation, and in particular, to the application of tumor markers in liver cancer prognosis, severity evaluation and liver cancer treatment. Background Art

[0002] Liver cancer remains one of the most difficult cancers to effectively treat clinically, mainly due to the profound gap in people's understanding of its underlying pathogenesis. At present, there is an urgent need to decipher the complex molecular mechanisms that control the progression of liver cancer. Although tumor markers such as AFP have been used in clinical practice, there are still many liver cancer patients who do not have elevated AFP, and targeted drugs for AFP have not yet been developed. Therefore, finding reliable liver cancer markers is crucial for the prevention and control of liver cancer.

[0003] THY1, also known as CD90, is a glycoprotein widely expressed on the surface of various cells. It has gained significant attention in cancer research due to its involvement in tumor progression, cell-cell adhesion, and cell signaling responses [1,2]. Notably, THY1 expression is elevated in certain cancer types, such as breast cancer, pancreatic cancer, and lung cancer [3]. Low expression of THY1 is associated with better prognosis and longer overall survival in these malignancies. THY1 is also associated with various aspects of tumor occurrence and development. It can promote tumor cell proliferation and migration, thereby enabling tumor growth and metastasis. In addition, THY1 can enhance the stemness and self-renewal ability of tumor cells, promote tumor treatment resistance and tumor recurrence [4]. THY1 is expressed not only in tumor cells, but also in tumor-associated fibroblasts (CAFs), which play a vital role in tumor growth, metastasis, and treatment resistance [5,6]. However, existing technologies for the prognosis of liver cancer require the combination of multiple markers, which have the problems of complicated types of detection markers and high detection costs, and lack a single marker that can be used to accurately predict the prognosis of liver cancer.

[0004] References:

[0005] 1.Kumar,A.,Bhanja,A.,Bhattacharyya,J.,and Jaganathan,BG(2016).Multiple roles of CD90 in cancer.Tumour Biol 37,11611-11622.10.1007 / s13277-016-5112-0.

[0006] 2.Zhou,Y.,Meng,X.,He,W.,Li,X.,Zhao,R.,Dong,C.,Yuan,D.,Yang,J.,Zhang,R.,Shi,G.,et al.(2022).USF1 / CD90 signaling in maintaining glioblastoma stemcells and tumor-associated macrophages adhesion.Neuro Oncol 24,1482-1493.10.1093 / neuonc / noac063.

[0007] 3.True,L.D.,Zhang,H.,Ye,M.,Huang,C.Y.,Nelson,P.S.,von Haller,P.D.,Tjoelker,L.W.,Kim,J.S.,Qian,W.J.,Smith,R.D.,et al.(2010).CD90 / THY1 isoverexpressed in prostate cancer-associated fibroblasts and could serve as acancer biomarker.Mod Pathol 23,1346-1356.10.1038 / modpathol.2010.122.

[0008] 4.Shaikh,M.V.,Kala,M.,and Nivsarkar,M.(2016).CD90 a potential cancerstem cell marker and a therapeutic target.Cancer Biomark 16,301-307.10.3233 / CBM-160590.

[0009] 5.Zeng,F.,Gao,M.,Liao,S.,Zhou,Z.,Luo,G.,and Zhou,Y.(2023).Role andmechanism of CD90(+)fibroblasts in inflammatory diseases and malignanttumors.Mol Med 29,20.10.1186 / s10020-023-00616-7.

[0010] 6.Pascal,LE,Ai,J.,Vencio,RZ,Vencio,EF,Zhou,Y.,Page,LS,True,LD,Wang,Z.,and Liu,AY(2011).Differential Inductive Signaling of CD90Prostate Cancer-Associated Fibroblasts Compared to Normal Tissue StromalMesenchyme Cells.Cancer Microenviron 4,51-59.10.1007 / s12307-010-0061-4.

[0011] In view of this, the present invention is proposed. Summary of the invention

[0012] The purpose of the present invention is to provide the application of tumor markers in the prognosis and severity assessment of liver cancer and the treatment of liver cancer to solve the above technical problems.

[0013] The present invention is achieved in that:

[0014] In a first aspect, the present invention provides a use of a reagent for detecting tumor marker levels in the preparation of a liver cancer severity assessment product or a prognosis product, wherein the tumor marker is THY1.

[0015] In a second aspect, the present invention provides the use of a THY1 gene expression inhibitor in the preparation of a drug for preventing or treating liver cancer.

[0016] The present invention has the following beneficial effects:

[0017] The present invention has discovered through screening that the tumor marker THY1 can predict the severity and prognosis of liver cancer. THY1 is upregulated in liver cancer, and its expression level is related to the prognosis of liver cancer patients. THY1 regulates liver cancer cell apoptosis, cell cycle and epithelial-mesenchymal transition, thereby enhancing liver cancer cell proliferation, migration and invasion. Using THY1 as a liver cancer tumor marker, corresponding reagents for detecting tumor marker levels can be developed, which are further used to prepare liver cancer severity assessment products or prognosis products. Reagents for detecting tumor marker levels include but are not limited to reagents for detecting the levels of DNA, RNA, protein or cells with tumor markers of tumor markers. The tumor markers provided by the present invention only need to detect one marker to quickly and accurately realize the assessment of the severity and prognosis of liver cancer. This use has the characteristics of low detection cost, simple result interpretation, accurate assessment results, and high specificity.

[0018] Experiments have shown that knocking out THY1 can slow tumor growth and prolong the survival of nude mouse liver cancer models. Therefore, inhibiting the expression of the THY1 gene can slow the growth rate, migration, and invasion of liver cancer, and can be used for the prevention and treatment of liver cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0020] Figure 1 This is the experimental result diagram showing that THY1 is higher in liver cancer tissue than in adjacent tissues;

[0021] Figure 2 The results of the experiment on the effect of THY1 on the prognosis of liver cancer patients are shown in Figure 2. (A) In the TCGA and GEO databases, the overall survival and disease-free survival of liver cancer patients with high THY1 expression were shorter than those with low THY1 expression. (B) Among the 108 tissue specimens collected, the overall survival of liver cancer patients with high THY1 expression was shorter than that of liver cancer patients with low THY1 expression.

[0022] Figure 3 The results of the experiment on THY1 promoting the malignant biological behavior of liver cancer cells; (A) CCK-8 experiments confirmed that overexpression of THY1 can promote the proliferation of liver cancer cells; (B and C) Flow cytometry and TUNEL experiments confirmed that overexpression of THY1 can inhibit the apoptosis of liver cancer cells. (D) Flow cytometry experiments confirmed that THY1 can affect the cell cycle of liver cancer cells; (E) Transwell experiments confirmed that overexpression of THY1 can promote the invasion of liver cancer cells;

[0023] Figure 4 The statistical results of THY1 affecting the growth of subcutaneous tumors and survival time in nude mice; (A and B) knocking down THY1 can inhibit the growth of subcutaneous tumors in nude mice; (C) knocking down THY1 can prolong the survival time of nude mice with subcutaneous tumors;

[0024] Figure 5 The RT-PCR validation results of MTIF, FCN3, CYP1A2, CYP3A4, APOF, HAMP, MT1G, NCAPG, ILF2, FADS1, SIPA1L2, and SPINK1 are shown;

[0025] Figure 6 The statistical results of THY1 (A) and PRC1 (B) expression in liver cancer tissues and adjacent tissues are shown in Figure 2.

[0026] Figure 7 The correlation analysis between THY1 and overall survival time of liver cancer (A) and the correlation analysis between PRC1 and overall survival time of liver cancer (B);

[0027] Figure 8 Volcano plot of differentially expressed genes in 108 HCC tumor tissue samples. DETAILED DESCRIPTION

[0028] References to embodiments of the present invention will now be provided in detail, one or more examples of which are described below. Each example is provided as an explanation rather than a limitation of the present invention. In fact, it will be apparent to those skilled in the art that various modifications and variations may be made to the present invention without departing from the scope or spirit of the present invention. For example, a feature illustrated or described as part of one embodiment may be used in another embodiment to produce a further embodiment.

[0029] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, molecular biology (including recombinant techniques), microbiology, biochemistry, and immunology, which are within the capabilities of a skilled artisan. This technique is fully explained in the literature, such as Molecular Cloning: A Laboratory Manual, 2nd Edition (Sambrook et al., 1989); Oligonucleotide Synthesis (MJ Gait, ed., 1984); Animal Cell Culture (RI Freshney, ed., 1987); Methods in Enzymology (Academic Press, Inc.); Handbook of Experimental Immunology (DM Weir and CC Blackwell, eds.); Gene Transfer Vectors for Mammalian Cells (JM Miller and MP Calos, eds., 1987); Current Protocols in Molecular Biology (FM Ausubel et al., eds., 1987); PCR: The Polymerase Chain Reaction (PCR: The Polymerase Chain Reaction) (Academic Press, Inc., 1987). Reaction" (Mullis et al., eds., 1994); and Current Protocols in Immunology (JE Coligan et al., eds., 1991), each of which is expressly incorporated herein by reference.

[0030] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0031] The term "biomarker" or "marker" broadly refers to any detectable compound or cell present in or derived from a sample, such as a protein, peptide, proteoglycan, glycoprotein, lipoprotein, cell, or a distinguishing molecule or distinguishing fragment of any of the above substances. For example, detection of a specific antibody or binding to a specific antibody can indicate the presence of a specific antigen (e.g., protein) in a sample. Here, a distinguishing molecule or fragment is a molecule or fragment that indicates the presence or abundance of the above-identified compound or cell when detected. Biomarkers can, for example, be separated from a sample, measured directly in a sample, or detected or determined in a sample. Biomarkers can, for example, be functional, partially functional, or non-functional.

[0032] Specifically, a tumor marker refers to a biomarker substance that appears in the serum, urine, tissue and other samples of tumor patients. Its presence indicates that tumor cells may exist in the body. Tumor markers can be used to detect these markers to achieve early diagnosis of tumors, monitor disease progression and evaluate treatment effects. Since the presence and content of tumor markers are related to factors such as the type, location, size, and malignancy of the tumor, early diagnosis and disease monitoring of tumors can be achieved by detecting tumor markers, which is conducive to improving the success rate of tumor treatment and the survival rate of patients. Cell surface markers refer to substances such as proteins and sugars that exist on the surface of tumor cells. Changes in cell surface markers can reflect the growth status and characteristics of tumor cells and are the most common type of tumor markers. Intracellular markers refer to substances such as proteins and RNA that exist inside tumor cells.

[0033] The term "sample" refers to a biological specimen obtained or derived from a target individual, the source of which may be fresh, frozen and / or preserved organ or tissue samples or solid tissues generated from biopsies or primers; blood or any blood component. The term "sample" includes biological specimens that have been manipulated in any way after their acquisition, such as by reagent treatment, stabilization, or enrichment for certain components (such as proteins or polynucleotides), or embedded in a semi-solid or solid matrix for sectioning purposes.

[0034] In a first aspect, the present invention provides a use of a reagent for detecting tumor marker levels in the preparation of a liver cancer severity assessment product or a prognosis product, wherein the tumor marker is THY1.

[0035] Through long-term and extensive screening experiments, the present invention has discovered a tumor marker THY1 that can predict the severity and prognosis of liver cancer. THY1 is upregulated in liver cancer, and its expression level is related to the prognosis of liver cancer patients. THY1 regulates liver cancer cell apoptosis, cell cycle and epithelial-mesenchymal transition, thereby enhancing liver cancer cell proliferation, migration and invasion. Using THY1 as a liver cancer tumor marker, corresponding reagents for detecting tumor marker levels can be developed, which are further used to prepare liver cancer severity assessment products or prognosis products. Reagents for detecting tumor marker levels include but are not limited to reagents for detecting the levels of DNA, RNA, protein or cells with tumor markers of tumor markers. The tumor marker provided by the present invention only needs to detect one marker to quickly and accurately realize the assessment of the severity and prognosis of liver cancer. This use has the advantages of low detection cost, simple result interpretation, accurate assessment results, and high specificity.

[0036] In a preferred embodiment of the present invention, liver cancer is primary liver cancer and secondary liver cancer.

[0037] In a preferred embodiment of the present invention, the liver cancer is selected from hepatocellular carcinoma or fibrolamellar liver cancer.

[0038] In a preferred embodiment of the present invention, the detection reagent is a reagent for detecting the level of DNA, RNA, protein of a tumor marker or cells carrying a tumor marker.

[0039] In a preferred embodiment of the present invention, the detection reagent is a reagent for detecting tumor marker DNA in a sample by polymerase chain reaction, real-time fluorescence quantitative polymerase chain reaction, and / or nucleic acid mass spectrometry; the detection reagent includes but is not limited to: primers and / or probes. For example, detection primers or probes are designed to cover the above tumor marker sites.

[0040] The detection reagent is a reagent for detecting the RNA level of tumor markers in a sample by RT-PCR technology, fluorescent quantitative PCR technology, RNA Sequencing, and RNA array. The detection reagent includes but is not limited to: primers and / or probes.

[0041] In a preferred embodiment of the present invention, the detection reagent is a reagent for detecting the level of tumor marker protein in a sample by ELISA, Western blotting and / or Elisopt method, or a reagent for detecting the level of cells carrying tumor markers in a sample by TUNEL detection and / or flow cytometry.

[0042] In a preferred embodiment of the present invention, the liver cancer severity assessment product or prognosis product is at least one of a primer, a probe, a chip and a membrane strip; when the product is a primer and / or a probe, the form of the product includes but is not limited to lyophilized powder, liquid and the like.

[0043] In a preferred embodiment of the present invention, the liver cancer severity assessment product or prognosis product is a kit. When the product is a kit, the kit also includes an amplification buffer, a solvent, a washing solution (or a rinsing solution), a color developing solution, a stop solution, and the like.

[0044] In a preferred embodiment of the present invention, the application includes: if the THY1 level in the tested sample is significantly increased compared with normal tissue, the liver cancer is assessed to be severe or the prognosis is poor; significantly increased means that compared with normal tissue, the THY1 level in the tested sample is statistically significantly or extremely significantly increased.

[0045] The sample to be tested is body fluid and / or punctured tissue of liver cancer, liver cancer hyperplasia, or liver precancerous lesions;

[0046] The body fluid includes but is not limited to at least one of blood, urine and puncture fluid.

[0047] Blood includes but is not limited to: whole blood, serum, plasma, separated nucleated cells, circulating tumor cells in blood, and exosomes in blood.

[0048] In a second aspect, the present invention provides the use of a THY1 gene expression inhibitor in the preparation of a drug for preventing or treating liver cancer.

[0049] In an optional embodiment, the inhibitor is a product prepared or screened with THY1 gene as the target and having an inhibitory effect on the THY1 gene; the product is an sgRNA targeting the THY1 gene; the sgRNA targeting the THY1 gene is shown in SEQ ID NO.1: aaccaacttcaccagcaaataca.

[0050] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0051] The present invention conducted a variety of in vitro and in vivo experiments, including CCK8, flow cytometry and TUNEL assays to analyze cell proliferation and apoptosis in liver cancer cells, and evaluated the effect of THY1 on cell cycle progression through cell cycle assay analysis. Transwell and scratch assays were used to explore the effect of THY1 on liver cancer cell migration and invasion. In addition, the effect of THY1 knockdown on tumor growth and survival was evaluated using a nude mouse subcutaneous tumor model.

[0052] Example 1

[0053] In this example, tissue microarray analysis and RNA-seq analysis were performed on multiple samples.

[0054] By sequencing 108 tumor tissue samples from Sichuan Provincial People's Hospital using the 10× Genomics platform, genes whose expression increased more than twofold were collectively analyzed, with upregulated genes highlighted in red and downregulated genes highlighted in green. Figure 8 The volcano plot shown shows the differentially expressed genes in HCC tumor specimens, and 824 upregulated genes and 971 downregulated genes were found. In addition, RNA-seq analysis of 362 tissue samples from Sichuan Provincial People's Hospital found 1055 upregulated genes and 1362 downregulated genes.

[0055] By taking the intersection of these differentially expressed genes, 337 differentially expressed genes were found (106 up-regulated genes and 231 down-regulated genes).

[0056] Among these 337 genes, THY1 ranked at the top in terms of fold difference. Further analysis of the CPTAC database revealed that THY1 was elevated in liver cancer compared with adjacent tissues. Western blotting and RT-PCR were performed on 14 pairs of liver cancer patients' cancer and adjacent tissues.

[0057] Western blotting

[0058] For protein extraction, whole cell lysates were prepared using RIPA buffer. After protein extraction, western blotting was performed. Proteins were separated from the samples using 4% to 20% SDS-PAGE. Then, the protein bands were transferred to a nitrocellulose membrane and the membrane was blocked with 5% BSA. The primary antibody was added to the membrane and then incubated overnight at 4°C. After incubation with the appropriate secondary antibody, the developer was added and scanned using the Tanon image system.

[0059] RT-PCR detection: Total RNA was obtained by lysis with TRIzol reagent, and then reverse transcribed into cDNA using a reverse transcription kit (TaKaRa). Reverse transcription and PCR were performed according to the instructions of TaKaRa RT-PCR Kit (Cat. No. RR064A). The reverse transcription program was: 42°C, 5 min; 95°C, 10 s; 1 cycle. The PCR program was: 95°C, 5 s; 60°C, 20 s, repeated 40 cycles. SYBR Green Premix PCR Master Mix was used for RT-PCR experiments on the ABI HT9600 instrument.

[0060] Volume(ul) Final concentration 2×One Step RT-PCR BufferⅢ 10 TaKaRa Ex Taq HS (5U / μl) 0.4 SYBR Green Premix PCR Master Mix 0.4 PCR Forward Primer (10μM) 0.4 0.2μM PCR Reverse Primer (10μM) 0.4 0.2μM Total RNA 6 <![CDATA[RNase Free dH2O]]> 2.4 Total 20

[0061] The primer sequences for amplifying THY1 are shown in Table 1.

[0062] RT-PCR test results refer to Figure 1As shown in the figure, in 14 patients with liver cancer, the expression level of THY1 in liver cancer tissues was higher than that in adjacent tissues.

[0063] In the microarray of 108 liver cancer patients, it was also found that the proportion of THY1 high expression in liver cancer was higher than that in adjacent cancer tissues.

[0064] Example 2

[0065] Analysis of the TCGA database revealed that THY1 expression levels were correlated with the survival time of liver cancer patients.

[0066] By analyzing the TCGA database, Figure 2 The results of Figure A in Figure 1 show that the overall survival time and disease-free survival time of patients with high THY1 expression are shorter than those with low THY1 expression. And through the analysis of the data collected from 108 patients, it was also found that the overall survival time of patients with high THY1 expression was shorter than that of patients with low THY1 expression ( Figure 2 The staining depth score and the range score were added together to obtain a total score. 0-3 points represent "low" expression, and 4-7 points represent "high" expression.

[0067] Example 3

[0068] This example conducts an experiment on the effect of THY1 on the function of liver cancer cells.

[0069] The experimental method of Hep3B or HepG2 cells overexpressing or knocking down THY1 is as follows:

[0070] One day before transfection, Hep3B or HepG2 cells were seeded in 24-well plates with 0.5 mL of Opti-MEM cell culture medium containing FBS and antibiotics. The number of cells selected for initial seeding should allow the cells to reach 70-90% confluence within 24 hours. Add 20 pmol siRNA (or 0.8 μg pcDNA3.1-h-THY1, the nucleotide sequence of the exogenous gene h-THY1-CDs transfected into the target cells is shown in SEQ ID NO.2, the full length of the pcDNA3.1-h-THY1 plasmid is shown in SEQ ID NO.3, and h-THY1-CDs is connected to the pcDNA3.1 plasmid by double enzyme digestion (NheI and ApaI)) to 50 μl Opti-MEM serum-free medium and mix gently; mix the lipofectamin reagent, dilute 1 μl lipofectamin reagent with 50 μl serum-free Opti-MEM (when transfecting DNA, add 2 μl lipofectamin reagent), mix gently, and leave at room temperature for 5 minutes; mix the diluted siRNA and Lipofectamin reagent; mix gently, and leave at room temperature for 20 minutes to form a siRNA / lipofectamin (or DNA / lipofectamin) complex. Add 100 μl of siRNA / lipofectamin (or DNA / lipofectamin) complex to the wells of the culture plate containing cells and culture medium, and gently shake the cell culture plate back and forth. After the cells are incubated at 37°C in a CO2 incubator for 24h-48h, other post-transfection detection steps are performed. The sgRNA targeting the THY1 gene is shown in SEQ ID NO.1: aaccaacttcaccagcaaataca.

[0071] (1) CCK-8 experiment

[0072] In a 96-well plate, transfected Hep3B or HepG2 cells were grown at a density of 500 cells / well. After the predetermined incubation time, CCK-8 solution was added to each well, incubated at 37°C for 30 minutes, and the absorbance was measured at 450 nm using a reader.

[0073] (2) Flow cytometry analysis of cell cycle

[0074] For cell cycle analysis, hepatoma cells Hep3B or HepG2 were collected by trypsinization and fixed in 70% ethanol at 4°C overnight. The cells were then placed in PBS containing 0.1% Triton-X-100 and 100 μg / mL RNase A at 37°C for 30 minutes, followed by PBS containing 50 μg / mL PI at 37°C for another 30 minutes. Data were acquired by FACS Vantage flow cytometer and analyzed using FlowJo software.

[0075] (3) Flow cytometry analysis of cell apoptosis

[0076] For apoptosis analysis, liver cancer cells were immersed in PBS containing 5 μL of Annexin V-FITC and 50 μg / mL of PI in a dark room for 30 minutes. Cell apoptosis was then analyzed using flow cytometry. Cell percentage In the early stages of apoptosis, data were obtained by counting the ratio of the number of cells positively stained with Annexin V-FITC and negatively stained with PI.

[0077] (4) EdU experiment

[0078] Hepatoma cells were seeded onto glass coverslips and cultured in serum-free medium for 48 hours. Subsequently, the cells were incubated with EdU (50 μM, Ruibo Bio, Cat# C10310-3) for 2 hours. 50 μL of cell fixative (PBS containing 4% paraformaldehyde) was added to each well and incubated at room temperature for 30 minutes, and the fixative was discarded. 50 μL of 2 mg / mL glycine was added to each well, and the glycine solution was discarded after incubation on a decolorizing shaker for 5 minutes. 100 μL of PBS was added to each well, and the decolorizing shaker was washed for 5 minutes, and the PBS was discarded. 100 μL of permeabilization solution (0.5% Triton X-100 in PBS) was added to each well and incubated on a decolorizing shaker for 10 minutes; PBS was washed once for 5 minutes. 100 μL of 1*Apollo staining reaction solution was added to each well, and the staining reaction solution was discarded after incubation on a decolorizing shaker for 30 minutes at room temperature and away from light. Add 100 μL of permeabilization solution (0.5% Triton X-100 in PBS) and wash 2-3 times on a decolorizing shaker for 10 minutes each time, then discard the permeabilization solution. Cell nuclei are labeled with DAPI. The labeled cells are observed under a microscope.

[0079] (5) Clone formation experiment

[0080] The colony formation ability of liver cancer cells was determined using a clone formation assay. Hep3B or HepG2 cells overexpressing THY1 were uniformly seeded in 6-well plates at a density of 500 cells / well. The culture medium was replaced every 2 days for 2 weeks. After paraformaldehyde fixation and crystal violet staining, photos and data were collected.

[0081] (6) Transwell experiment

[0082] The invasion ability of liver cancer cells was detected by Transwell assay. Transfected cells (4*10 4 ) were placed in the top chamber, while fresh DMEM containing 10% FBS was added to the bottom chamber. After 48 hours, the cells from the top chamber were transferred to the lower chamber. After fixation, the surviving cells were stained, and the cells transferred to the lower chamber were fixed, observed under a microscope, and images were acquired.

[0083] (7) Scratch test

[0084] The cell migration ability was assessed by scratch test. After the cell density reached 80-90% after transfection, the cells were scraped using a pipette tip perpendicular to the bottom of the 6-well plate. The results were recorded by taking pictures at 0 and 48 hours.

[0085] CCK-8 assay ( Figure 3 Figure A in Figure 2 confirmed that overexpression of THY1 can enhance the activity of liver cancer cells. Flow cytometry experiment ( Figure 3 Figure B) confirmed that overexpression of THY1 can inhibit apoptosis of liver cancer cells and promote cell cycle progression. Figure 3 C in Figure ) and cell clones ( Figure 3 The D figure in Figure 2 confirmed that THY1 can promote the proliferation of liver cancer cells. In addition, the transwell experiment ( Figure 3 E) and scratch experiments also confirmed that THY1 can enhance the migration ability of liver cancer cells.

[0086] Example 4

[0087] Inhibition of THY1 inhibited the growth of subcutaneous tumors in nude mice.

[0088] Subcutaneous tumor formation in nude mice:

[0089] 5×10 6 Hep3B liver cancer cells with THY1 knockdown were injected subcutaneously into BALB / c nude mice of about 4 weeks old (10 nude mice in each group), and the tumor volume was observed and detected every 4 days. The tumor volume was calculated using the following formula: tumor volume = width × length × (width + length) × 0.5. The nude mice were euthanized on the 30th day.

[0090] Figure 4 The results showed that inhibiting THY1 slowed down the growth of subcutaneous tumors in nude mice and reduced tumor weight. In addition, inhibiting THY1 prolonged tumor survival.

[0091] Example 5

[0092] Among the potential candidate genes, further RT-PCR validation results showed that there was no significant difference in the expression levels of 12 genes, including MTIF, FCN3, CYP1A2, CYP3A4, APOF, HAMP, MT1G, NCAPG, ILF2, FADS1, SIPA1L2, and SPINK1, between liver cancer and adjacent tissues ( Figure 5 ).

[0093] The amplification primer sequence information for RT-PCR of each target gene is shown in Table 1 below. The kit and method used for amplification are the same as those in Example 1.

[0094] Table 1 RT-PCR amplification primer sequences

[0095] Gene Upstream primer Downstream primer Species MT1F atggaccccaactgctcctg ttagccacagccccagacca human FCN3 ctccggtgccaggaaggccc ggtgtccatgtcacaaaaga human CYP1A2 tggccagagcttgaccttca ggatgaggaagctgggtcag human CYP3A4 cgactctctcaacaatccac cagatatttaatacttcaag human APOF tgggaaccttctacaacctg atcagaaggtcatatcccag human HAMP cttgcctcctgctcctcctc cagctctgtcctggggttgc human MT1G gaccccaactgctcctgtgc gggcagcaggagcagcagct human NCAPG tcaggattttgcaaggaaac tcagttggtcaaagattgcc human ILF2 tcgaaaactggatccagaac tcaagtccttcagtagtctg human FADS1 tggctcaccctttgggtctt cccaaagtcatgctgcagcc human SIPA1L2 agtacttgaaagatctggcg atgatggccccaatgctaaa human SPINK1 gggactgatggaaatactta cccagatttttgaatgagga human PRC1 tggagtatgtggcagaacaa tgttcgaggagcgctgccat human THY1 gccatgagaataccagcagt ggtatgtgtgctcaggcacc human β-actin tgctatccctgtacgcctct caggtcccggccagccaggt human

[0096] After expanding the sample size (80 pairs of liver cancer tissues and adjacent tissues), among the 14 genes including the above 12 genes, THY1 and PRC1 genes, only the expression levels of THY1 and PRC1 were significantly higher in liver cancer tissues than in adjacent tissues ( Figure 6 ).

[0097] The overall survival rate of 80 liver cancer patients after the sample size was expanded was analyzed and it was found that the overall survival rate of 40 liver cancer patients with high THY1 expression was significantly lower than that of 40 liver cancer patients with low THY1 expression ( Figure 7 A in the figure). The overall survival rate of patients with high PRC1 expression was lower than that of liver cancer patients with low PRC1 expression, but there was no significant difference between the two groups ( Figure 7 B). These results suggest that THY1 can be used as a prognostic marker for liver cancer with good accuracy.

[0098] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. Use of a reagent for detecting tumor marker levels in the preparation of a liver cancer severity assessment product or a prognosis product, characterized in that: The tumor marker is THY1.

2. The use according to claim 1, characterized in that: The liver cancer includes primary liver cancer and secondary liver cancer.

3. The use according to claim 2, characterized in that: The liver cancer is selected from hepatocellular carcinoma or fibrolamellar liver cancer.

4. The use according to claim 1, characterized in that: The reagent for detecting the level of a tumor marker is a reagent for detecting the level of DNA, RNA, protein of the tumor marker or cells carrying the tumor marker.

5. The use according to claim 4, characterized in that: The reagent for detecting the level of tumor markers is a reagent for detecting the tumor marker DNA in a sample by polymerase chain reaction, real-time fluorescence quantitative polymerase chain reaction, and / or nucleic acid mass spectrometry; The detection reagent is a reagent for detecting the RNA level of the tumor marker in a sample through RT-PCR technology, fluorescent quantitative PCR technology, RNA Sequencing, and RNA array.

6. The use according to claim 4, characterized in that: The detection reagent is a reagent for detecting the protein level of the tumor marker in a sample by ELISA, Western blotting and / or Elisopt method, or a reagent for detecting the level of cells carrying the tumor marker in a sample by TUNEL detection and / or flow cytometry.

7. The use according to claim 1, characterized in that: The liver cancer severity assessment product or prognosis product is at least one of a primer, a probe, a chip and a membrane strip.

8. The use according to claim 1, characterized in that: The liver cancer severity assessment product or prognosis product is a kit.

9. The use according to claim 1, characterized in that: The application includes: if the THY1 level in the tested sample is significantly increased compared with normal tissue, the severity of liver cancer or poor prognosis is assessed; The sample to be tested is body fluid and / or punctured tissue of liver cancer, liver cancer hyperplasia, or liver precancerous lesions; The body fluid is selected from at least one of blood, urine and puncture fluid.

10. Application of THY1 gene expression inhibitors in the preparation of drugs for the prevention or treatment of liver cancer.